Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

801. Radical prostatectomy versus watchful waiting in early prostate cancer. Full Text available with Trip Pro

Radical prostatectomy versus watchful waiting in early prostate cancer. In 2002, we reported the initial results of a trial comparing radical prostatectomy with watchful waiting in the management of early prostate cancer. After three more years of follow-up, we report estimated 10-year results.From October 1989 through February 1999, 695 men with early prostate cancer (mean age, 64.7 years) were randomly assigned to radical prostatectomy (347 men) or watchful waiting (348 men). The follow-up (...) was complete through 2003, with blinded evaluation of the causes of death. The primary end point was death due to prostate cancer; the secondary end points were death from any cause, metastasis, and local progression.During a median of 8.2 years of follow-up, 83 men in the surgery group and 106 men in the watchful-waiting group died (P=0.04). In 30 of the 347 men assigned to surgery (8.6 percent) and 50 of the 348 men assigned to watchful waiting (14.4 percent), death was due to prostate cancer

2005 NEJM Controlled trial quality: predicted high

802. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Full Text available with Trip Pro

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Clinically localized prostate cancer is very prevalent among US men, but recurrence after treatment with conventional radiation therapy is common.To evaluate the hypothesis that increasing the radiation dose delivered to men with clinically localized prostate cancer improves disease outcome.Randomized controlled trial of 393 patients (...) with stage T1b through T2b prostate cancer and prostate-specific antigen (PSA) levels less than 15 ng/mL randomized between January 1996 and December 1999 and treated at 2 US academic institutions. Median age was 67 years and median PSA level was 6.3 ng/mL. Median follow-up was 5.5 (range, 1.2-8.2) years.Patients were randomized to receive external beam radiation to a total dose of either 70.2 Gy (conventional dose) or 79.2 Gy (high dose). This was delivered using a combination of conformal photon

2005 JAMA Controlled trial quality: uncertain

803. The use of bisphosphonates in men with hormone-refractory prostate cancer

The use of bisphosphonates in men with hormone-refractory prostate cancer The use of bisphosphonates in men with hormone-refractory prostate cancer The use of bisphosphonates in men with hormone-refractory prostate cancer Berry S, Waldron T, Winquist E, Lukka H, Genitourinary Cancer Disease Site Group CRD summary This review concluded that bisphosphonates may reduce bone pain in hormone-refractory prostate cancer, but the evidence was not so robust. Although some details of the review (...) that further investigations to identify the role of bisphosphonates alone and in combination with other treatments in men with HRPC are warranted. Funding Cancer Care Ontario; Ontario Ministry of Health and Long-term Care. Bibliographic details Berry S, Waldron T, Winquist E, Lukka H, Genitourinary Cancer Disease Site Group. The use of bisphosphonates in men with hormone-refractory prostate cancer. Cancer Care Ontario Practice Guidelines Initiative. 2005. Evidence-based Series 3-14. Available at: [Accessed

2005 DARE.

804. Vaccines for metastatic hormone-refractory prostate cancer

Assessment. Vaccines for metastatic hormone-refractory prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4 Authors' objectives The aim of this study was to summarize the available information on the use of Sipuleucel-T [Provenge (formerly APC8015)] and granulocyte macrophage-colony stimulating factor (GM-CSF) gene-transduced tumour vaccine (GVAX) as therapeutic vaccines in men with metastatic hormone-refractory prostate cancer (HRPC). Authors (...) ' conclusions There are no therapeutic vaccines approved for use for prostate cancer in Canada or the US. To be effective, a therapeutic vaccine must demonstrate the ability to elicit an appropriate tumour-specific response, and have a favourable safety profile. Provenge is safe and well-tolerated. It targets a specific protein for prostate cancer and demonstrates a statistically significant survival benefit. Further clinical trials should compare Provenge with the current treatment standard (Taxotere plus

2005 Health Technology Assessment (HTA) Database.

805. Atrasentan for metastatic hormone refractory prostate cancer

Atrasentan for metastatic hormone refractory prostate cancer Atrasentan for metastatic hormone refractory prostate cancer Atrasentan for metastatic hormone refractory prostate cancer Murphy G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Murphy G. Atrasentan for metastatic hormone refractory prostate cancer. Ottawa: Canadian (...) Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4 Authors' objectives The aim of this report is to summarize the available information on the use of atrasentan (Trade Mark Xinlay, manufactured by Abbott Laboratories) for the treatment of metastatic hormone refractory prostate cancer. Authors' conclusions An anti-cancer drug from a new class of agents called selective endothelin-A receptor antagonists, this drug is being studied in a subset of patients with advanced prostate cancer

2005 Health Technology Assessment (HTA) Database.

806. Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer

pertaining to the safety, effectiveness and cost effectiveness of prostate specific antigen testing for the diagnosis and management of prostate cancer, the current funding arrangements remain unchanged. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Immunoassay; Prostate-Specific Antigen; Prostatic Neoplasms Language Published English Country of organisation Australia Address for correspondence MDP 107, GPO Box 9848, Canberra ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 (...) Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality

2005 Health Technology Assessment (HTA) Database.

807. Cryotherapy as primary treatment for localized prostate cancer (update)

Cryotherapy as primary treatment for localized prostate cancer (update) Cryotherapy as primary treatment for localized prostate cancer (update) Cryotherapy as primary treatment for localized prostate cancer (update) Alberta Heritage Foundation for Medical Research Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alberta Heritage Foundation (...) for Medical Research. Cryotherapy as primary treatment for localized prostate cancer (update) Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). Technote TN 54. 2005 Authors' objectives This Technote has been prepared in response to a request from Capital Health for an update on the status of cryotherapy for the primary treatment of localized prostate cancer. Authors' conclusions Cryotherapy, when used as primary treatment for localized prostate cancer, is a promising technology based

2005 Health Technology Assessment (HTA) Database.

808. Cryotherapy as a primary treatment for prostate cancer

Cryotherapy as a primary treatment for prostate cancer Cryotherapy as a primary treatment for prostate cancer Cryotherapy as a primary treatment for prostate cancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Cryotherapy as a primary treatment for prostate cancer. London (...) : National Institute for Clinical Excellence (NICE) 2005: 2 Authors' objectives This study aims to assess the current evidence on cryotherapy as a primary treatment for prostate cancer. Authors' conclusions 1.1 Current evidence on the safety and efficacy of cryotherapy, measured by reduction of prostate specific antigen (PSA) levels and biopsy findings, appears adequate to support the use of this procedure as a primary treatment in patients with prostate cancer provided that normal arrangements

2005 Health Technology Assessment (HTA) Database.

809. High-intensity focused ultrasound for prostate cancer

High-intensity focused ultrasound for prostate cancer High-intensity focused ultrasound for prostate cancer High-intensity focused ultrasound for prostate cancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. High-intensity focused ultrasound for prostate cancer. London (...) : National Institute for Clinical Excellence (NICE) 2005: 2 Authors' objectives This study aims to assess the current evidence on high-intensity focused ultrasound for prostate cancer. Authors' conclusions 1.1 Current evidence on the safety and efficacy of high-intensity focused ultrasound (HIFU), as measured by reduction in prostate-specific antigen (PSA) levels and biopsy findings, appears adequate to support the use of this procedure for the treatment of prostate cancer provided that the normal

2005 Health Technology Assessment (HTA) Database.

810. Cryotherapy for recurrent prostate cancer

of cryotherapy for recurrent prostate cancer on quality of life and long-term survival remain uncertain. Clinicians should therefore ensure that patients understand the uncertainties and the alternative treatment options. Use of the Institute's Information for the public is recommended. 1.3 Further research and audit should address quality of life, clinical outcomes and long-term survival. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cryotherapy; Prostatic Neoplasms /surgery (...) Cryotherapy for recurrent prostate cancer Cryotherapy for recurrent prostate cancer Cryotherapy for recurrent prostate cancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Cryotherapy for recurrent prostate cancer. London: National Institute for Clinical Excellence (NICE

2005 Health Technology Assessment (HTA) Database.

811. Diagnostic value of systematic prostate biopsy methods in the investigation for prostate cancer: a systematic review

. Authors' conclusions Schemes, which apply additional laterally directed cores, showed a higher cancer yield. It still has to be demonstrated that extended biopsy schemes with a higher cancer yield do lead to a survival benefit due to early cancer detection. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Biopsy /methods; Diagnostic Techniques, Surgical; Prostatic Neoplasms /diagnosis Language Published English Country of organisation England Address for correspondence University (...) Diagnostic value of systematic prostate biopsy methods in the investigation for prostate cancer: a systematic review Diagnostic value of systematic prostate biopsy methods in the investigation for prostate cancer: a systematic review Diagnostic value of systematic prostate biopsy methods in the investigation for prostate cancer: a systematic review Eichler K, Wilby J, Hempel S, Myers L, Kleijnen J Record Status This is a bibliographic record of a published health technology assessment from

2005 Health Technology Assessment (HTA) Database.

812. Low dose rate brachytherapy for localised prostate cancer

. The Institute has issued a cancer service guideline on Improving Outcomes in Urological Cancers ( 1.4 Further research and audit should address quality of life, clinical outcomes and long-term survival. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Brachytherapy; Prostatic Neoplasms Language Published English Country of organisation England Address for correspondence MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800; Fax: +44 020 7067 5801 Email: nice (...) Low dose rate brachytherapy for localised prostate cancer Low dose rate brachytherapy for localised prostate cancer Low dose rate brachytherapy for localised prostate cancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Low dose rate brachytherapy for localised prostate

2005 Health Technology Assessment (HTA) Database.

813. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/mL: systematic review and meta-analysis

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/mL: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

814. Racial differences in prostate cancer treatment outcomes: a systematic review

tumours) and included patients with metastatic and non-metastatic prostatic cancer. In most studies (69%) at least 20% of the participants were black. Outcomes assessed in the review Studies that assessed the difference between races in treatment outcomes were eligible for inclusion. The included studies assessed prostatic-specific antigen (PSA) failure, overall survival, disease-specific survival and disease-free survival. The studies followed up patients from at least 1 month to a median of 96 (...) Study designs of evaluations included in the review The inclusion criteria for study design were not defined. Specific interventions included in the review Studies of radical prostatectomy, hormonal therapy and radiation therapy were eligible for inclusion. Participants included in the review Studies of black and white men receiving equal treatment for prostate cancer were eligible for inclusion. The included studies were undertaken in patients with varying disease severity (from stage 1 to stage 4

2005 DARE.

815. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer

of finasteride chemoprophylaxis would have a substantial impact on health care costs, it is likely to have only a limited effect on prostate cancer mortality. Further research is needed to investigate the increased number of high-grade tumours observed with finasteride in the original trial, and to determine whether these tumours are associated with more aggressive disease and shorter survival. Studies of other chemoprevention agents for prostate cancer are currently underway, and it is imperative (...) to identify the model parameters. The outcomes assessed included: the number of true high-grade prostate cancer cases among the finasteride trial arm; the proportion of untreated men diagnosed with high-grade prostate cancer disease; the increase or decrease in observed Surveillance, Epidemiology and End Results registry (SEER) incidence of prostate cancer (overall); the prevalence of benign prostatic hyperplasia requiring care among those aged younger than 65 years; the prevalence of benign prostatic

2005 NHS Economic Evaluation Database.

816. Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects Full Text available with Trip Pro

, the reduction in prostate cancers was accompanied by an absolute increase in higher Gleason grade (ie, more aggressive) cancers in the finasteride treated group as well as increased incidence of sexual side effects. For this reason, the question is whether finasteride is most effective in prevention of clinically insignificant cancers and ineffective in prevention of tumours that are more likely to lead to metastatic disease and death—or perhaps even increases the risk as suggested by the study results (...) Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects Finasteride reduced prostate cancer but led to more high grade tumours and sexual side effects | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts

2004 Evidence-Based Medicine

817. Living with untreated localised prostate cancer was seen as living under a dark shadow Full Text available with Trip Pro

previously and chose watchful waiting (regular checks of LPC instead of surgery or radiotherapy) as their primary treatment; spoke Swedish; and had no chronic disease that could affect daily life. Methods Men were individually interviewed in their homes for 45–60 minutes about their feelings and beliefs about LPC. The interviews had 2 foci: “tell me about your experience when the disease was diagnosed,” and “tell me about your experience of being a patient with prostate cancer.” Interviews were tape (...) talking about sexual problems and preferred discussing their impotence with other men. (4) The physician—a companion. Routine visits to the same physician who had time to discuss various aspects of the disease helped men to feel safe, secure, and confident. Men perceived relationships with their physicians as close or even as friendships, and talked about “we” when describing discussions of future treatment strategies. Conclusions Living with untreated localised prostate cancer can be understood

2004 Evidence-Based Nursing

818. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. (Abstract)

tumor stage could predict the time to death from prostate cancer and death from any cause after radical prostatectomy.As compared with an annual PSA velocity of 2.0 ng per milliliter or less, an annual PSA velocity of more than 2.0 ng per milliliter was associated with a significantly shorter time to death from prostate cancer (P<0.001) and death from any cause (P=0.01). An increasing PSA level at diagnosis (P=0.01), a Gleason score of 8, 9, or 10 (P=0.02), and a clinical tumor stage of T2 (P<0.001 (...) ) also predicted the time to death from prostate cancer. For men with an annual PSA velocity of more than 2.0 ng per milliliter, estimates of the risk of death from prostate cancer and death from any cause seven years after radical prostatectomy were also influenced by the PSA level, tumor stage, and Gleason score at diagnosis.Men whose PSA level increases by more than 2.0 ng per milliliter during the year before the diagnosis of prostate cancer may have a relatively high risk of death from prostate

2004 NEJM

819. Natural history of early, localized prostate cancer. Full Text available with Trip Pro

-defined catchment area in central Sweden (recruitment March 1977 through February 1984).A consecutive sample of 223 patients (98% of all eligible) with early-stage (T0-T2 NX M0 classification), initially untreated prostatic cancer. Patients with tumor progression were hormonally treated (either by orchiectomy or estrogens) if they had symptoms.Progression-free, cause-specific, and overall survival.After complete follow-up, 39 (17%) of all patients experienced generalized disease. Most cancers had (...) % confidence interval, 22-88) beyond 15 years of follow-up (P =.01).Although most prostate cancers diagnosed at an early stage have an indolent course, local tumor progression and aggressive metastatic disease may develop in the long term. These findings would support early radical treatment, notably among patients with an estimated life expectancy exceeding 15 years.

2004 JAMA

820. Patient education materials about the treatment of early-stage prostate cancer: a critical review. (Abstract)

Patient education materials about the treatment of early-stage prostate cancer: a critical review. To ensure that patients make informed medical decisions, patient education materials must communicate treatment risks and benefits.To survey publicly available patient education materials and assess their suitability to support informed decision making in early-stage prostate cancer.Cross-sectional review of Internet, print, and multimedia sources.University data analysis laboratory.The content (...) , and plain-language reviews were evaluated by 1 reviewer. The criteria reflect the authors' focus on informed decision making. Other aspects of health education may require a different evaluation template.Currently available patient education materials on early-stage prostate cancer treatment do not contain comprehensive information about the risks and benefits of each treatment. To assist patients and physicians in choosing among prostate cancer treatment options, a new generation of materials is needed.

2004 Annals of Internal Medicine